USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
September 2025
Afimkibart: Treatment of ulcerative colitis and Crohn’s disease
Amtabafusp alfa: Treatment of HIV infection
Branosotine: Veterinary product intended to increase the lifespan in dogs
Canvuparatide: Treatment of hypoparathyroidism
Canvuparatide hydrochloride: Treatment of hypoparathyroidism
Cizutamig: Treatment of multiple myeloma
Dezandrodeg: Treatment of prostate cancer
Efgitasialase alfa: Antineoplastic, treatment of advanced solid tumors
Galvokimig: Treatment of atopic dermatitis
Leuprolide: Palliative treatment of prostate cancer
Leuprolide mesylate: Palliative treatment of prostate cancer
Nebokitug: Treatment of inflammatory diseases
Nivisnebart: Treatment of Alzheimer’s disease (AD) and Parkinson’s disease (PD)
Orevandrodeg: Treatment of prostate cancer
Plixorafenib: Antineoplastic
Privosegtor: Indicated for optic neuroprotection and treatment of neuropathies
Remzistotug: Antineoplastic
Repinatrabit: Treatment of Phenylketonuria (PKU)
Solnerstotug: Antineoplastic
Sonpiretigene isteparvovec: Treatment of retinitis pigmentosa and Stargardt disease
Torvutatug: Treatment of solid tumors
Torvutatug samrotecan: Treatment of solid tumors
Traxivitug: Antiviral, prevention and treatment of BKV disease in kidney transplant patients
August 2025
Alimatravir: Prevention and treatment of HIV
Avigbagene parvec: Treatment of Gaucher disease
Brenipatide: Treatment of type 2 Diabetes Mellitus
Cetoquagene parvec: Treatment of salivary gland hypofunction and xerostomia
Curcumin: Treatment of cellulite, subcutaneous fat and Dercum’s disease lipoma
Donzakimig: Treatment of atopic dermatitis
Lemuplamor: Treatment of acute ischemic stroke
Onrogadgene parvec: Treatment of Parkinson’s Disease (PD)
Remigromig: Treatment of retinal diseases, including diabetic macular edema (DME) and neovascular age related macular degeneration (nAMD)
Resveratrol: Treatment of cellulite, subcutaneous fat and Dercum’s disease lipoma
Sonditecan: Antineoplastic
Soralimixin: Antibacterial
Soralimixin sulfate: Antibacterial
Tonobafusp alfa: Antineoplastic
Tusamitamab sonditecan: Antineoplastic
Vanoglipel: Treatment of metabolic dysfunction-associated steatohepatitis and Type 2 diabetes
Vepugratinib: Antineoplastic
Vonaprument: Prevention of vision loss in patients with dry advanced molecular degeneration
Vuragadgene parvec: Treatment of Parkinson’s Disease (PD)
July 2025
Actinium AC 225 Alpitatug Satetraxetan: Antineoplastic, treatment of prostate cancer
Alpitatug: Antineoplastic, treatment of prostate cancer
Balinatunfib: Treatment of inflammatory and autoimmune diseases
Bofanglutide: Treatment of diabetes and obesity
Brivekimig: Treatment of hidradenitis suppurativa
Docirbrutinib: Treatment of B-cell malignancies
Docirbrutinib mesylate: Treatment of B-cell malignancies
Emestedastat: Treatment of Alzheimer’s disease, enhancing cognition
Etuvetidigene autotemcel: Treatment of Wiskott-Aldrich Syndrome
Intismeran autogene: Antineoplastic
Lonvoguran: Treatment of hereditary angioedema (HAE)
Mavrostobart: Antineoplastic
Naperiglipron: Treatment of diabetes and chronic weight management
Naperiglipron erbumine: Treatment of diabetes and chronic weight management
Pasritamig: Treatment of metastatic castration-resistant prostate cancer (mCRPC)
Peluntamig: Antineoplastic
Petrelintide: Treatment of obesity
Precemtabart: Antineoplastic, treatment of solid tumors
Precemtabart tocentecan: Antineoplastic, treatment of solid tumors
Rupatadine: Treatment of allergic rhinitis and chronic idiopathic urticaria
Rupatadine fumarate: Treatment of allergic rhinitis and chronic idiopathic urticaria
Tiratricol: Treatment of MCT8 deficiency (also known as Allan-Herndon-Dudley syndrome (AHDS))
Tocentecan: Antineoplastic, treatment of solid tumors
Spevatamig: Antineoplastic
Vicadrostat: Treatment of chronic kidney disease
